Clinical Trial Update: Dolutegravir Impact on Residual Replication [Phase 4]

View source ↗

Summary

Phase 4 trial results evaluate dolutegravir's impact on residual HIV replication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Tivicay (dolutegravir)

Snippet

Sponsor: University of Melbourne | Conditions: HIV | Phase 4 | Status: COMPLETED